Therapeutic potential of endothelin receptor antagonists in diabetes.
Endothelins (ETs) are widely distributed in the body and perform several vascular and non-vascular functions. Experimental evidence indicates that abnormalities of the ET system occur in several organs affected in chronic diabetic complications. Furthermore, ET antagonists were found to prevent structural and functional changes in the target organs of chronic diabetic complications in animal models. Abnormalities of plasma ET levels have also been demonstrated in human diabetes. This review discusses the role of ET in the pathogenesis of chronic diabetic complications. The current experimental evidence suggests that ET antagonism may potentially represent an adjuvant therapeutic tool in the treatment of chronic diabetic complications.
Chakrabarti
S
S
Department of Pathology, DSB 4011, The University of Western Ontario, London, Ontario, Canada. schakrab@julian.uwo.ca
Cukiernik
M
M
Mukherjee
S
S
Chen
S
S
D000818:Animals; D003920:Diabetes Mellitus / Q000188:drug therapy*; D065128:Endothelin Receptor Antagonists; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use*
D065128:Endothelin Receptor Antagonists; D007004:Hypoglycemic Agents